Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Aug 14, 2025-

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all dose…